Latest news with #TheJacksonLaboratory
Yahoo
19-05-2025
- Business
- Yahoo
Humanized Mouse and Rat Model Market Report 2025 - Market to Hit USD 409.8 Million by 2030
Humanized mouse models dominate the market type segment, expected to maintain the fastest growth through 2030 due to their utility in drug discovery and immuno-oncology research. North America leads the market, primarily driven by U.S. advancements. Key players include Charles River Laboratories and The Jackson Laboratory. Growing demand for specialized testing and the rise of CROs & CDMOs present further opportunities. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Humanized Mouse and Rat Model Market by Type, Application, End User, and Region - Global Forecast to 2030" report has been added to report segments the market by type, application, end user, and region, covering core factors like drivers, challenges, and opportunities influencing growth. It provides a detailed analysis of leading players, examining their products, strategies, and recent developments. The global humanized mouse and rat model market is projected to grow from USD 276.2 million in 2025 to USD 409.8 million in 2030, reflecting a robust CAGR of 8.2%. This growth is driven by increased R&D investments in pharmaceutical and biopharmaceutical sectors. The expansion of R&D pipelines is increasing the demand for outsourcing analytical testing, heightened by concentrated research initiatives on rare diseases and orphan drugs. The expensive nature of in-house drug development further fuels this trend, along with technological advancements, novel drug discovery techniques, and a rising demand for specialized testing services. Humanized Mouse Model Segment Leads The market is divided into humanized mouse models and humanized rat models. In 2024, humanized mouse models dominated the revenue share and saw the fastest CAGR growth. The surge in demand for cell-based humanized mouse models is powering this segment's expansion, supporting applications in drug safety and efficacy analysis, long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease. Immunology & Infectious Diseases: A Key Segment The humanized mouse and rat model market is segmented by application into several areas, including oncology and neuroscience. The immunology & infectious diseases segment held the second-largest market share in 2024. Mouse models are pivotal in immunology and inflammation studies, facilitating detailed analyses of immunological processes through targeted alterations in the mouse genome. Pharmaceutical & Biotechnology Sector to Record Highest Growth Among end users, pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes are significant segments. Pharmaceutical & biotechnology companies dominated in 2024 due to increasing expenditure on innovative drug development and the shift towards personalized medicine. However, the CROs & CDMOs segment is predicted to have the highest growth, driven by rising outsourcing of preclinical studies and drug development activities. US Market Growth Leading the Way The market is categorized by geography into regions such as North America, Europe, and Asia Pacific. North America led in 2024, with the United States at the forefront, backed by substantial life sciences research funding and active research in mAbs and biosimilars. This dominance is also supported by a rising incidence of cancer. Competitive Landscape Key industry players include Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, JSR Corporation, Champions Oncology, and CLEA Japan Inc. Others are genOway, Inotiv, Janvier Labs, Altogen Labs, Vitalstar Biotechnology, Ingenious Targeting Laboratory, Reaction Biology, Harbour BioMed, Oncodesign Services, Pharmatest Services, Ozgene Pty Ltd., TransCure bioServices, Cyagen Biosciences, Aragen Life Sciences, GemPharmatech, and Biocytogen. Benefits of the Report: The report offers market leaders and new entrants close approximations of revenue numbers and valuable insights to enhance market positioning. It enables stakeholders to grasp market dynamics and devise effective strategies. Report Insights Include: Analysis of market drivers, like the increased use of humanized models in drug discovery. Detailed insights into product development and upcoming technologies. Comprehensive information on growth across varied regions. Exhaustive data on new products, untapped geographies, and market investments. In-depth competitive assessment of market leaders. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value in 2025 276.2 million Forecasted Market Value by 2030 409.8 million Compound Annual Growth Rate 8.2% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Rising Use of Humanized Models in Drug Discovery Research Emerging Preclinical Applications of Humanized Mouse Models Government-Funded Initiatives For Cancer Research Increasing R&D Activities in Pharmaceutical & Biotechnology Industry Restraints Introduction of FDA Modernization Act 2.0/3.0 Stringent Regulatory Compliance For Ethical Use of Animal Models Opportunities Growing Preference For Humanized PDX Models Emergence of Crispr in Biomedical Research Challenges Alternative Methods For Animal Testing Limitations of Humanized Mouse Models Company Profiles Charles River Laboratories The Jackson Laboratory Inotiv Genoway Taconic Biosciences, Inc. Jsr Corporation Champions Oncology, Inc. Janvier Labs Vitalstar Biotechnology Ingenious Targeting Laboratory Harbour Biomed Oncodesign Services Pharmatest Services Ozgene Pty Ltd. Clea Japan, Inc. Altogen Labs Reaction Biology Transcure Bioservices Cyagen Aragen Life Sciences Ltd. Biocytogen Gempharmatech For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Daily Mail
17-05-2025
- Health
- Daily Mail
Taking vitamin B could help to fight glaucoma, study finds
A common vitamin supplement could slow down the progression of the degenerative eye disease glaucoma, a study has found. Vitamin B, found in whole grains, dark leafy greens, such as kale and broccoli, eggs, fish and dairy, appears to diminish the damage caused by the condition. Glaucoma, which is suffered by nearly 700,000 people in the UK, is caused by an abnormality in the eye's drainage system causing fluid to build up, increasing pressure on the optic nerve. Primarily affecting older adults and those with a genetic disposition to the condition, it causes blurred vision and even blindness if left untreated. Glaucoma is usually managed by reducing the pressure through eye drops, surgery or laser treatments. The researchers gave supplements of vitamins B6, B9 and B12 to rats and mice with glaucoma. In rats with a more aggressive form of the disease, it slowed damage to the optic nerve. In mice with slower-developing glaucoma, the damage was halted completely. Scientists believe this could be due to the increased pressure in the eye changing the retina's ability to use vitamins which are crucial to maintaining healthy vision. Dr James Tribble, from the Karolinska Institute in Sweden, which carried out the study, said: 'The results are so promising that we have started a clinical trial, with patients already being recruited.' It comes after a 2019 study showed that vitamin B3 could be effective in preventing glaucoma. Scientists at The Jackson Laboratory in Maine, US, added B3 to water given to mice which were genetically predisposed to the condition. It kept their eyes healthier for longer compared to those given plain water.
